Response to comment on "Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer"

被引：0
|
作者：
van der Doelen, Maarten J. [1 ,2 ]
Slootbeek, Peter H. J. [1 ]
Mehra, Niven [1 ]
机构：
[1] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, POB 9101, NL-6500 HB Nijmegen, Netherlands
[2] Radboud Univ Nijmegen, Med Ctr, Dept Urol, Nijmegen, Netherlands
来源：
EUROPEAN JOURNAL OF CANCER | 2021年 / 144卷
关键词：
D O I：
10.1016/j.ejca.2020.11.041
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：395 / 396
页数：2
相关论文
共 50 条
  • [41] Overall survival using radium-223 (Ra223) in metastatic castrate-resistant prostate cancer (mCRPC) patients with and without DNA damage repair (DDR) defects
    van der Doelen, Maarten J.
    Velho, Pedro Isaacsson
    Slootbeek, Peter H. J.
    Naga, Samhita Pamidimarri
    Bormann, Maren
    van Helvert, Sjoerd
    Kroeze, Leonie I.
    van Oort, Inge M.
    Gerritsen, Winald R.
    Antonarakis, Emmanuel S.
    Mehra, Niven
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [42] Predictors for survival after radium-223 (R223) treatment for castration-resistant metastatic prostate cancer.
    Anderson, Eric
    Wong, William
    Mohammadi, Homan
    Daniels, Thomas Backus
    Tzou, Katherine S.
    Schild, Steven E.
    Keole, Sameer R.
    Choo, Richard
    Bryce, Alan H.
    Thai Huu Ho
    Quevedo, Fernando
    Vora, Sujay A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [43] Prognostic biomarkers in the use of radium-223 in patients with metastatic castration-resistant prostate cancer
    Vidal, M.
    Cardenas-Perilla, R.
    Delgado, A.
    Moron, S.
    Blair, J. L. Londono
    Vega, I.
    Ochoa, J. J. Correa
    Rojas, J.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2023, 42 (05): : 310 - 317
  • [44] Radium-223 Dichloride for Metastatic Castration-resistant Prostate Cancer: The Urologist's Perspective
    Shore, Neal D.
    UROLOGY, 2015, 85 (04) : 717 - 724
  • [45] EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer
    Thorsten D. Poeppel
    Daria Handkiewicz-Junak
    Michael Andreeff
    Alexander Becherer
    Andreas Bockisch
    Eva Fricke
    Lilli Geworski
    Alexander Heinzel
    Bernd J. Krause
    Thomas Krause
    Markus Mitterhauser
    Wilfried Sonnenschein
    Lisa Bodei
    Roberto C. Delgado-Bolton
    Michael Gabriel
    European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45 : 824 - 845
  • [46] Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223
    Rodriguez-Vida, A.
    Torregrosa, M. D.
    Pinto, A.
    Climent, M. A.
    Olmos, D.
    Carles, J.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2018, 20 (06): : 679 - 686
  • [47] EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer
    Poeppel, Thorsten D.
    Handkiewicz-Junak, Daria
    Andreeff, Michael
    Becherer, Alexander
    Bockisch, Andreas
    Fricke, Eva
    Geworski, Lilli
    Heinzel, Alexander
    Krause, Bernd J.
    Krause, Thomas
    Mitterhauser, Markus
    Sonnenschein, Wilfried
    Bodei, Lisa
    Delgado-Bolton, Roberto C.
    Gabriel, Michael
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (05) : 824 - 845
  • [48] When to Initiate Treatment With Radium-223 in Patients With Metastatic Castration-Resistant Prostate Cancer
    Shore, Neal D.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (01) : 26 - 29
  • [49] Radium-223 plus abiraterone in metastatic castration-resistant prostate cancer: a cautionary tale
    Sedhom, Ramy
    Antonarakis, Emmanuel S.
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2019, 8 : S341 - S345
  • [50] Radium-223 in metastatic castration-resistant prostate cancer: current status and future perspectives
    Wyndaele D.N.J.
    Tijdschrift voor Urologie, 2020, 10 (6-7) : 131 - 140
12345